The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Much as it is good to be associated with cutting edge research, I suppose we have to ask what could be the impact on our bottom line in coming years. I initially bought in here (at 50p -eek!) in the hope that forward osmosis would be such a successful technology the world would be falling over themselves to build huge desalination plants. Not really worked out like that has it? Would be good to think that the combination of our technology and graphene might kickstart that part of our business again. Any water experts out there care to comment?
Can't get my head round the American healthcare system but it seems the uncertainty around reform there is really hitting us right now. Must be a very difficult market to sell into right now. Question for investors is how long is this going to go on for - is this a perfect way to stock up cheap for a great company with a great product or is this just going to rumble for years. I topped up at 16.75. No much I can do now except wait.
Fall is presumably down to Trump tweeting again last night about cracking down on pharma prices.
Thanks for the info guys - I see that it will have an impact on the bottom line then.
Awarding of full accreditation under Renewable Obligations Order and the receipt of Renewables Obligations Certificates is "a truly momentous occasion" according to Tim Cornelius. Could anyone explain why?
Great piece in Newsweek. We've seen these articles in specialist laundry industry media but it's got to be positive to see more in the mainstream press. http://europe.newsweek.com/almost-waterless-washers-use-beads-help-save-environment-554511
By the by a bit - well a lot maybe - but it was interesting see the BBC 2 history programme Britain's Ancient Capital this week. It showed how Neolithic culture might have spread south from Orkney by building a whale bone and hide boat and paddling across to the mainland edging by Stroma. It was a perilous journey and the narrative made a huge deal out of the terrific tidal flows that rip through that stretch of water.
Well this is interesting - up a third on very little volume. Anyone know any known reason? I seem to remember a couple of years back there was a spike over a false rumour concerning Google - maybe it's that malarkey again.
Hundreds of trades in the last two days - barely any of them creeping over 1000 quid. What's that all about? Also - great to hear from today's rns that Oxford Nanaopore is starting to motor - I would think that is the company that will seriously affect the sp here.
Hundreds of trades in the last two days - barely any of them creeping over 1000 quid. What's that all about? Also - great to hear from today's rns that Oxford Nanaopore is starting to motor - I would think that is the company that will seriously affect the sp here.
Surely we can now expect a boom! ;-) http://www.thedailymash.co.uk/news/celebrity/beyonce-announces-collaboration-with-greggs-20160419108110
I don't engage with this charting/TA stuff, though good luck to those who can make it work for them, and I prefer just to look at what's happening in the companies. I make it that Oxford Nanopore accounts for around 40 per cent of the fair value of our portfolio and it's that that probably steers the share price. There's all sorts of companies that could go big here - I'm in TRX, Ceres, Summit as well - but its Oxford Nanopore that is by far the biggest stone in the pan. When we start to get more of a sense of how that's doing - and it seems we're not far from that - we may see things happen to price here.
"trouble is I've had too many 1st half figures that have been awful with the notion that the 2nd half will be grand..and guess what it never happens!" That's not *quite* true really is it? 2015/16 first half results - 0.7m loss; final results - 0.3m profit. With increased turnover I don't see why the swing shouldn't be bigger.
Pom - they've got ex-US for £40m (plus the £20-odd million when the last trial patients is dosed) if it's a completely dud drug. If it does work and is a success, then its well over 10 times that amount.
I bought at 135p. No point to make here other than if I can't tell you people that I made £16.65 (plus divis) for every share, who can I tell? Sadly I only bought £500 worth. It was, I think, the second share I ever bought - those mobile phones look they could be popular was my thinking. Sadly subsequent punts have not, by and large, been as inspired.
Woodford's move to sell was widely reported on 21 June. It's on his own website: He said "In terms of portfolio disposals, we sold the trust’s shares in Tissue Regenix, BTG and Midatech Pharma to raise cash. Positions in Abzena and IP Group were slightly reduced. We remain positive on the long-term potential of all of these businesses and continue to hold the shares across a range of our other portfolios."
Woodford's move to sell was widely reported on 21 June. It's on his own website: He said "In terms of portfolio disposals, we sold the trust’s shares in Tissue Regenix, BTG and Midatech Pharma to raise cash. Positions in Abzena and IP Group were slightly reduced. We remain positive on the long-term potential of all of these businesses and continue to hold the shares across a range of our other portfolios."